Amryt to enrol youngest patients to test potential EB treatment with market value more than €1 billion

Amryt Pharma can now enrol young Epidermolysis Bullosa (EB) patients between the ages of 21 days to 4 years old to test AP101 as a potential treatment.

Amryt said in the press release that the Independent Data Monitoring Committee’s (IDMC) analysis was conducted using pharmacokinetic (“PK”) data received from patients already enrolled in the trial (aged four years and older).

Amryt added the EASE trial is the largest ever global Phase III study conducted in patients with EB. Amryt said it expects top-line data read out in H2 2019.

It is estimated that the market potential for AP101 is more than €1 billion, Amryt said.

Joe Wiley, CEO of Amryt Pharma, commented: “Extending the age eligibility criteria for this trial is positive news and a significant step forward in addressing the unmet need in this devastating condition, which is present from birth in most cases. This development represents another milestone for Amryt as we build on our vision of becoming a global leader in rare and orphandiseases.”